AbbVie (NYSE:ABBV) said it now expects to report acquired IPR&D and milestone expenses of $1.6B on a pre-tax basis for Q4, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback